Biotech ETFs Had A Rough 3rd Quarter By: ETFdb October 02, 2019 at 08:00 AM EDT Amid intensifying scrutiny of drug pricing and other political pressures, biotechnology ETFs and active mutual funds endured some rough sledding in the third quarter. Read More >> Related Stocks: Nasdaq Biotechnology Ishares ETF S&P Biotech SPDR Vaneck Biotech ETF